| Impact of Antiviral Therapy on Gastroesophageal Varices. (NCT02758509) | Parc de Salut Mar | 2010-01-01 |
| PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) (NCT01056172) | Pusan National University Yangsan Hospital | 2010-01-01 |
| Role of FXR in Hepatitis C Virus Replication (NCT01492998) | Hospices Civils de Lyon | 2010-01-01 |
| Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance (NCT00927290) | French National Agency for Research on AIDS and Viral Hepatitis | 2009-12-03 |
| Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care (NCT01012895) | Bristol-Myers Squibb | 2009-12-01 |
| The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin (NCT01025765) | National Taiwan University Hospital | 2009-11-01 |
| Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C (NCT01018615) | University of North Carolina, Chapel Hill | 2009-11-01 |
| Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers (NCT01274013) | Avera McKennan Hospital & University Health Center | 2009-10-01 |
| Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus (NCT00971308) | Bristol-Myers Squibb | 2009-10-01 |
| Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects (NCT00983957) | Bristol-Myers Squibb | 2009-10-01 |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection (NCT00962936) | CureTech Ltd | 2009-09-01 |
| Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed (NCT00968357) | SciClone Pharmaceuticals | 2009-09-01 |
| A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 (NCT00790673) | Can-Fite BioPharma | 2009-07-01 |
| Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (NCT00882193) | University of Nebraska | 2009-05-01 |
| Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity (NCT00957866) | University of Manitoba | 2009-05-01 |
| Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C (NCT00876174) | University of Nebraska | 2009-04-15 |
| Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123) (NCT00828269) | Merck Sharp & Dohme LLC | 2009-04-01 |
| Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis (NCT00840489) | Hospital Universitario Ramon y Cajal | 2009-01-01 |
| Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients (NCT00881582) | King Abdulaziz Medical City | 2009-01-01 |
| A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients (NCT00854802) | Debiopharm International SA | 2009-01-01 |
| A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects (NCT00722358) | Bristol-Myers Squibb | 2008-12-01 |
| Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy (NCT00749138) | Bader, Ted, M.D. | 2008-11-01 |
| Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus (NCT00800007) | Anza Therapeutics, Inc. | 2008-11-01 |
| High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (NCT00830609) | Dr. Conrado Fernandez | 2008-11-01 |
| Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients (NCT00596960) | US Department of Veterans Affairs | 2008-11-01 |
| Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (NCT00780910) | Tanabe Pharma Corporation | 2008-11-01 |
| Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection (NCT00782353) | Hoffmann-La Roche | 2008-10-01 |
| Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection (NCT00823862) | Dynavax Technologies Corporation | 2008-10-01 |
| Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C (NCT00778843) | Catalysis SL | 2008-10-01 |
| Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients (NCT00759200) | Novartis | 2008-10-01 |
| High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1 (NCT00735969) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2008-08-01 |
| A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects (NCT00664625) | Bristol-Myers Squibb | 2008-05-01 |
| A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects (NCT00663208) | Bristol-Myers Squibb | 2008-05-01 |
| HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients (NCT00703872) | Hepasome Pharmaceuticals | 2008-05-01 |
| Hepatitis C Treatment and Atherosclerosis (NCT00659256) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2008-04-08 |
| Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment (NCT00680342) | National Center for Complementary and Integrative Health (NCCIH) | 2008-04-01 |
| High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 (NCT00662220) | Foundation for Liver Research | 2008-04-01 |
| Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients (NCT00571714) | University of Nebraska | 2008-04-01 |
| Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients (NCT00637923) | Romark Laboratories L.C. | 2008-03-01 |
| A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects (NCT00559247) | Bristol-Myers Squibb | 2008-01-01 |
| Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) (NCT02106156) | Hoffmann-La Roche | 2008-01-01 |
| Safety and PK Study of MP-424 to Treat Chronic Hepatitis C (NCT00591214) | Tanabe Pharma Corporation | 2007-12-01 |
| Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR (NCT00532701) | National Taiwan University Hospital | 2007-11-01 |
| High Dose Ribavirin in the Treatment of Chronic Hepatitis C (NCT00944684) | University of Bern | 2007-11-01 |
| A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects (NCT00546715) | Bristol-Myers Squibb | 2007-11-01 |
| An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants (NCT00528528) | Tibotec BVBA | 2007-10-01 |
| Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels (NCT00575627) | University of Turin, Italy | 2007-09-01 |
| A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment (NCT00537407) | Debiopharm International SA | 2007-09-01 |
| Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment (NCT00519792) | Intarcia Therapeutics | 2007-08-01 |
| A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (NCT00522808) | Arrow Therapeutics | 2007-08-01 |
| The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection (NCT00556504) | TCM Biotech International Corp. | 2007-07-01 |
| Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C (NCT00495391) | Romark Laboratories L.C. | 2007-07-01 |
| Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients (NCT00526448) | Hospital Carlos III, Madrid | 2007-06-01 |
| Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C (NCT00491244) | National Taiwan University Hospital | 2007-06-01 |
| Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin (NCT00487318) | Bader, Ted, M.D. | 2007-06-01 |
| S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C (NCT00475176) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2007-05-01 |
| Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients (NCT01290965) | Scynexis, Inc. | 2007-04-01 |
| Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study (NCT00466271) | National Taiwan University Hospital | 2007-04-01 |
| Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896) (NCT01340573) | Merck Sharp & Dohme LLC | 2007-03-23 |
| Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV) (NCT00446134) | Bausch Health Americas, Inc. | 2007-03-01 |
| Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C (NCT00433108) | Antipodean Pharmaceuticals, Inc. | 2007-03-01 |
| Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 (NCT00411385) | Human Genome Sciences Inc. | 2007-02-01 |
| Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C (NCT00629824) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2007-02-01 |
| HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b (NCT01342003) | Azienda Ospedaliera San Camillo Forlanini | 2007-02-01 |
| Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin (NCT00641654) | Göteborg University | 2007-01-01 |
| Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone (NCT00433069) | University Hospital, Geneva | 2007-01-01 |
| Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma (NCT00834860) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2007-01-01 |
| Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides (NCT00445419) | Pevion Biotech Ltd | 2006-12-01 |
| Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha. (NCT00408304) | Bnai Zion Medical Center | 2006-12-01 |
| Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients (NCT00402428) | Human Genome Sciences Inc. | 2006-12-01 |
| Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV) (NCT01545544) | ANRS, Emerging Infectious Diseases | 2006-11-01 |
| Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C (NCT00540345) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2006-10-01 |
| Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin (NCT00395421) | Merck Sharp & Dohme LLC | 2006-10-01 |
| Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients (NCT01684787) | Miguel Santin | 2006-09-01 |
| Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance (NCT00370617) | University of Turin, Italy | 2006-09-01 |
| 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C (NCT00763568) | Romark Laboratories L.C. | 2006-08-01 |
| Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients (NCT00680173) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2006-08-01 |
| Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma (NCT00630084) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2006-08-01 |
| Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C (NCT00372385) | Vertex Pharmaceuticals Incorporated | 2006-08-01 |
| Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation (NCT00375895) | Rennes University Hospital | 2006-06-01 |
| Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C (NCT00421434) | Romark Laboratories L.C. | 2006-06-01 |
| A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC) (NCT00304551) | Chugai Pharmaceutical | 2006-06-01 |
| Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects (NCT00926016) | Brooke Army Medical Center | 2006-06-01 |
| Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C (NCT00336479) | Vertex Pharmaceuticals Incorporated | 2006-06-01 |
| A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (NCT00332176) | BioWest Therapeutics Inc | 2006-06-01 |
| Continuing Treatment With Pegasys and Copegus (NCT00336518) | Májbetegekért Alapítvány | 2006-06-01 |
| Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin (NCT00491179) | National Taiwan University Hospital | 2006-06-01 |
| Treatment Insulin Resistence in HCV G-1 Patient (NCT00546442) | Valme University Hospital | 2006-05-01 |
| RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin (NCT00485342) | Hospices Civils de Lyon | 2006-04-01 |
| Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies (NCT00530972) | Hospital Carlos III, Madrid | 2006-03-01 |
| Virological Response Study of the HCV Vaccine IC41 (NCT00601770) | Valneva Austria GmbH | 2006-02-01 |
| Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen (NCT00286871) | Duke University | 2006-02-01 |
| Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan (NCT00543244) | National Taiwan University Hospital | 2006-01-01 |
| Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C (NCT00262379) | University Hospital, Angers | 2005-12-01 |
| Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) (NCT00736242) | Merck Sharp & Dohme LLC | 2005-12-01 |
| Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C (NCT00418054) | Romark Laboratories L.C. | 2005-12-01 |
| NIDDM and IR in Combination Therapy for CHC (NCT00687999) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2005-12-01 |
| Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV (NCT00611819) | University of Valencia | 2005-11-01 |
| Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C (NCT00322179) | Palo Alto Veterans Institute for Research | 2005-11-01 |
| A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 (NCT00656006) | Human Genome Sciences Inc. | 2005-11-01 |